[HTML][HTML] Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms–a practical guide to WHO-HAEM5

C Kühn, K Hörst, HM Kvasnicka, A Hochhaus… - Medizinische …, 2024 - degruyter.com
Abstract Within the World Health Organization (WHO) classification of haematopoietic
neoplasms, particularly its fifth version from 2022 (WHO-HAEM5), myeloid neoplasms are …

Prediction of deep molecular response in chronic myeloid leukemia using supervised machine learning models

Z Zad, S Bonecker, T Wang, I Zalcberg… - Leukemia …, 2024 - pubmed.ncbi.nlm.nih.gov
Prediction of deep molecular response in chronic myeloid leukemia using supervised machine
learning models Prediction of deep molecular response in chronic myeloid leukemia using …

[HTML][HTML] Fully Automated GeneXpert BCR-ABL1 Assay versus Standard Nonautomated BCR-ABL1 Real-Time Reverse Transcription–Polymerase Chain Reaction …

S More, T Chatterjee, C Agarwal, M Pujani… - Journal of Microscopy … - journals.lww.com
Background Molecular monitoring of chronic myeloid leukemia (CML) patients receiving
tyrosine kinase inhibitors at various time points after diagnosis is indispensable for …

[引用][C] Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms–a practical guide to WHO-HAEM5

A Hochhaus - Deutsche Nationalbibliothek

Leucemia mieloide crónica:¿ Es posible la remisión libre de tratamiento fuera de ensayos clínicos?

C Pavlovsky, RK Tannuri - Revista Hematología, 2023 - mail.revistahematologia.com.ar
La obtención de respuestas moleculares profundas para considerar la discontinuación de
tratamiento, es hoy uno de los objetivos en leucemia mieloide crónica (LMC). El beneficio …

[引用][C] Current Status of BCR:: ABL1 Quantitative PCR Analysis in Korea (2022)

자영이, 인숙김, 현영김… - Laboratory Medicine … - Korean Society for Laboratory …